drugset
drugset / Trial / NCT04469530

Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors

NCT04469530 ↗

Phase 2 Recruiting 55 enrolled Emory University Peach Bowl LegACy Fund · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The primary objective of this study is to improve the 2-year progression-free survival in children with high-risk solid tumors who are administered a maintenance regimen with continuous sirolimus administered on a backbone of metronomic chemotherapy following the completion of "standard" therapy, as compared to high-risk solid tumor patients treated with observation alone following completion of "standard" therapy.

Timeline

Start
2020-09-16
Primary completion
2029-02
Completion
2029-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Celecoxib Other / unclassified — Oral
Subject Cyclophosphamide Other / unclassified — Oral
Subject Etoposide Small molecule — Oral
Subject Sirolimus Small molecule 2 mg/m2 Oral

Indications

cancer